RESOLVING THE LEDGER
This is one outlet's own report from STAT — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 1 sources
A little-noticed policy shift by the Trump administration caused a seven-year delay in choosing a costly AbbVie medicine for Medicare price negotiations, a move likely to hurt taxpayers, according to an analysis by a consumer advocacy group.
The change occurred as the Centers for Medicare and Medicaid Services readied a new round of talks with drugmakers over prices that the agency would pay for a limited number of medicines. The process was created by the Inflation Reduction Act, which became law in 2022 in response to the rising cost of prescription drugs.
Continue to STAT+ to read the full story…
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.